---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268146"
form_type: "8-K"
ticker: "MBX"
cik: "0001776111"
company_name: "MBX Biosciences, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:54:02.920650+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MBX posts positive Phase 2 results for canvuparatide; Q3 net loss $21.6M; cash $391.7M

## Summary
- Q3 2025 net loss $21.6M vs $18.1M YoY; cash and equivalents $391.7M (includes $200M offering proceeds) funding into 2029.
- Positive Phase 2 topline: 63% of canvuparatide-treated patients met composite endpoint at 12 weeks; 79% at 6 months in open-label extension.
- Dosed first participant in Phase 1 trial of MBX 4291 (GLP-1/GIP co-agonist) for obesity; results from MAD portion expected Q4 2026.
- Dosed first patient in Phase 2a trial of imapextide for post-bariatric hypoglycemia; results expected Q2 2026.
- Director changes: James Cornelius resigned Oct 31; Steven Hoerter appointed executive chairman effective Nov 6, 2025.

## SEC filing metadata
- accession: 0001193125-25-268146
- form_type: 8-K
- ticker: MBX
- cik: 0001776111
- company_name: MBX Biosciences, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1776111/000119312525268146/0001193125-25-268146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1776111/000119312525268146/mbx-20251031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268146
- JSON: https://secwatch.observer/filing/0001193125-25-268146.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.